Hendrik Bergsma

713 total citations
9 papers, 554 citations indexed

About

Hendrik Bergsma is a scholar working on Oncology, Epidemiology and Neurology. According to data from OpenAlex, Hendrik Bergsma has authored 9 papers receiving a total of 554 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 7 papers in Epidemiology and 4 papers in Neurology. Recurrent topics in Hendrik Bergsma's work include Lung Cancer Research Studies (7 papers), Neuroendocrine Tumor Research Advances (7 papers) and Neuroblastoma Research and Treatments (4 papers). Hendrik Bergsma is often cited by papers focused on Lung Cancer Research Studies (7 papers), Neuroendocrine Tumor Research Advances (7 papers) and Neuroblastoma Research and Treatments (4 papers). Hendrik Bergsma collaborates with scholars based in Netherlands, Germany and Greece. Hendrik Bergsma's co-authors include Eric P. Krenning, Jaap J.M. Teunissen, Dik J. Kwekkeboom, Boen L.R. Kam, Mark Konijnenberg, Wouter W. de Herder, P.P.M. Kooij, Wouter A. van der Zwan, Katya Mauff and Esther I. van Vliet and has published in prestigious journals such as Journal of Nuclear Medicine, European Journal of Nuclear Medicine and Molecular Imaging and Best Practice & Research Clinical Gastroenterology.

In The Last Decade

Hendrik Bergsma

8 papers receiving 552 citations

Peers

Countries citing papers authored by Hendrik Bergsma

Since Specialization

Citations

This map shows the geographic impact of Hendrik Bergsma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hendrik Bergsma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hendrik Bergsma more than expected).

Fields of papers citing papers by Hendrik Bergsma

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hendrik Bergsma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hendrik Bergsma. The network helps show where Hendrik Bergsma may publish in the future.

Co-authorship network of co-authors of Hendrik Bergsma

This figure shows the co-authorship network connecting the top 25 collaborators of Hendrik Bergsma. A scholar is included among the top collaborators of Hendrik Bergsma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hendrik Bergsma. Hendrik Bergsma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

#	Work	Indexed citations
1	Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with ¹⁷⁷Lu-DOTATATE: Incidence, Course, and Predicting Factors in Patients with Gastroenteropancreatic Neuroendocrine Tumors 2017 ·Journal of Nuclear Medicine ·Hendrik Bergsma, Kirsten van Lom, Marc H.G.P. Raaijmakers, Mark Konijnenberg, (unknown), Jaap J.M. Teunissen, Wouter W. de Herder, Eric P. Krenning, Dik J. Kwekkeboom	104
2	Peptide Receptor Radionuclide Therapy & Oncology 2017 ·RePub (Erasmus University, Rotterdam) ·Hendrik Bergsma	0
3	Nephrotoxicity after PRRT with 177Lu-DOTA-octreotate 2016 ·European Journal of Nuclear Medicine and Molecular Imaging ·Hendrik Bergsma, Mark Konijnenberg, Wouter A. van der Zwan, Boen L.R. Kam, Jaap J.M. Teunissen, P.P.M. Kooij, Katya Mauff, Eric P. Krenning, Dik J. Kwekkeboom	128
4	[68Ga]NeoBomb1, a new potent GRPR-antagonist for PET imaging - Preclinical and first clinical evaluation in prostate cancer 2016 ·Berthold A. Nock, Aikaterini Kaloudi, (unknown), (unknown), Hendrik Bergsma, Dirk Müeller, Eric P. Krenning, Marion de Jong, Θεοδοσία Μάινα, Richard P. Baum	5
5	Subacute haematotoxicity after PRRT with 177Lu-DOTA-octreotate: prognostic factors, incidence and course 2015 ·European Journal of Nuclear Medicine and Molecular Imaging ·Hendrik Bergsma, Mark Konijnenberg, Boen L.R. Kam, Jaap J.M. Teunissen, P.P.M. Kooij, Wouter W. de Herder, Gaston J H Franssen, Casper H.J. van Eijck, Eric P. Krenning, Dik J. Kwekkeboom	126
6	Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [68Ga]SB3 and PET/CT 2015 ·European Journal of Nuclear Medicine and Molecular Imaging ·Θεοδοσία Μάινα, Hendrik Bergsma, Harshad Kulkarni, Dirk Müeller, (unknown), Eric P. Krenning, Berthold A. Nock, Marion de Jong, Richard P. Baum	91
7	Comparison of Response Evaluation in Patients with Gastroenteropancreatic and Thoracic Neuroendocrine Tumors After Treatment with [¹⁷⁷Lu-DOTA⁰,Tyr³]Octreotate 2013 ·Journal of Nuclear Medicine ·Esther I. van Vliet, Eric P. Krenning, Jaap J.M. Teunissen, Hendrik Bergsma, Boen L.R. Kam, Dik J. Kwekkeboom	39
8	PET/CT imaging with a novel 68Ga-labelled GRP-receptor antagonist, Sarabesin 3. First clinical data in patients with prostate and breast cancer 2013 ·Hendrik Bergsma, Harshad Kulkarni, Dirk Müeller, Θεοδοσία Μάινα, Berthold A. Nock, Eric P. Krenning, Marion de Jong, Richard P. Baum	3
9	Peptide receptor radionuclide therapy (PRRT) for GEP-NETs 2012 ·Best Practice & Research Clinical Gastroenterology ·Hendrik Bergsma, Esther I. van Vliet, Jaap J.M. Teunissen, Boen L.R. Kam, Wouter W. de Herder, Robin P. Peeters, Eric P. Krenning, Dik J. Kwekkeboom	58

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact